7 completed, 2 active not recruiting, 2 terminated. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 7, Active not recruiting 2, Terminated 2 |
Follow CERVARIX: new trials by email Literature Review of CERVARIX trials Research Report on CERVARIX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine - Human Papillomavirus-Related Cervical Carcinoma | Phase 4 | Active not recruiting | National Cancer Institute (NCI) | 5000 | 2022-03-01 | 2026-10-22 |
| Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine - Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma | Phase 4 | Active not recruiting | National Cancer Institute (NCI) | 27945 | 2017-11-29 | 2025-09-04 |
| FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program CERVARIX, GARDASIL - Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma | Phase 4 | Completed | Instituto Nacional de Salud Publica, Mexico | 3000 | 2017-01-03 | 2020-08-10 |
| Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) cervarix, Gardasil - Infection With Human Papillomavirus | Phase 4 | Completed | University Hospital, Ghent | 12 | 2013-06-25 | 2022-12-09 |
| Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults Gardasil, Cervarix - HIV, Human Papillomavirus | Phase 4 | Completed | University of Aarhus | 92 | 2011-08-01 | 2013-08-16 |
| Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil) - Infections, Papillomavirus, Papillomavirus Vaccines | Phase 4 | Completed | GlaxoSmithKline | 873 | 2010-10-26 | 2020-07-21 |
| Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination Cervarix, Engerix-B - Human Papillomavirus Infection | Phase 4 | Terminated | National Institute for Public Health and the Environment (RIVM) | 2010-09-01 | 2010-03-19 | |
| Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico Bivalent Vaccines, Tetravalent Vaccine - Healthy | Phase 4 | Completed | Instituto Nacional de Salud Publica, Mexico | 2000 | 2009-11-01 | 2018-08-27 |
| Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Cervarix, Gardasil - HPV Infections | Phase 4 | Completed | Public Health England | 400 | 2009-09-01 | 2020-10-01 |
| A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Cervarix - Human Papillomavirus Infection Leading to Cervical Cancer | Phase 4 | Terminated | GlaxoSmithKline | 743 | 2008-09-17 | 2019-11-05 |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents Cervarix, Engerix-B - Infections, Papillomavirus | Phase 4 | Completed | GlaxoSmithKline | 34412 | 2007-10-04 | 2019-11-15 |
Papillomavirus Infections (5) · Uterine Cervical Neoplasms (2) · Uterine Cervical Dysplasia (1)
GlaxoSmithKline (3) · Instituto Nacional de Salud Publica, Mexico (2) · National Cancer Institute (NCI) (2) · National Institute for Public Health and the Environment (RIVM) (1) · Public Health England (1) · University Hospital, Ghent (1) · University of Aarhus (1)
Costa Rica (2) · Mexico (2) · Belgium (1) · Brazil (1) · Denmark (1) · Estonia (1) · Finland (1) · India (1) · Philippines (1) · Thailand (1) · United Kingdom (1)
Aimee R Kreimer (2) · Aurelio Cruz, Valdez (1) · Eduardo C Lazcano, Phd, MD (1) · Geert Leroux-Roels, MD, PhD (1) · Janet L. Pacheco (1) · Lars Toft, MD (1)
PMID 41276263, PMID 23650505, PMID 24273179, PMID 24355090, PMID 24553190, PMID 25593103, PMID 28319456, PMID 29055031, PMID 29845626, PMID 30085139, PMID 30926298, PMID 31736068, PMID 31829767, PMID 32078808, PMID 32161969, PMID 32574384, PMID 33639181, PMID 33857679, PMID 34097688, PMID 34857420, PMID 35649600, PMID 41337735
2017 (1)